After three unsuccessful rounds of chemotherapy back in New Zealand, 57-year-old New Zealander Dale De Penning decided to ...

Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors ...

By Priyanjana Pramanik, MSc. IL-15 enhances the growth and survival of GPC3 CAR T cells, improving their ability to target ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, with a 5-year survival rate of 18%. Glypican-3 (GPC3) is a protein with high expression in HCC but not in healthy tissue, making ...

Researchers from Zymeworks Inc. presented preclinical data for the novel glypican-3 (GPC3)-targeting antibody-drug conjugate (ADC), ZW-251, being developed as an anticancer agent. ZW-251 shows optimal ...

Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma Aug 11, 2022 Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical ...